In this episode, Dr. Peter Lu and Dr. Jennifer Lee talk to Dr. Joel Rosh about the latest advances in pharmacologic treatment of pediatric inflammatory bowel disease. Dr. Rosh is Chief of Pediatric Gastroenterology, Liver Diseases and Nutrition at Cohen Children’s Medical Center, Northwell Health. He is a national board member for the Crohn’s and Colitis Foundation. We discuss the different classes of biologic and small molecules used in the treatment of pediatric inflammatory bowel disease including tips on challenging clinical scenarios, biosimilar medications, and insurance approval. Learning Objectives: Understand the differences between biologics, small molecules, biosimilar, and generic medicationsDiscuss the latest recommendations for treatment of inflammatory bowel disease when anti-TNF medications are no longer effectiveDiscuss clinical use case scenarios for anti-integrin antibodies, JAK inhibitors, IL13/IL23 inhibitors, IL23 inhibitor, and Sphingosine 1-phosphate receptor modulators.This episode is eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review! Support the showAs always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field. Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes!